Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positron emission tomography Clear all

Conditions: Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
Interventions: 18F-FDOPA; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Parkinson Disease
Interventions: Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020); Drug
Lead sponsor: Nicolaas Bohnen, MD, PhD; Other
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteer, Bone Alteration, Bone and Joint Cancer, Bone and Joint Infection, Arthritis
Interventions: 18F-NaF; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Alzheimer Disease, Frontotemporal Dementia, Dementia
Interventions: [18F]RP-115 PET/MRI or PET/CT and MRI; Drug
Lead sponsor: David Wilson; Other
Eligibility: 40 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IB3 Cervical Cancer
Interventions: Fludeoxyglucose F-18, Gadobutrol, Magnetic Resonance Imaging, Positron Emission Tomography; Other · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer
Interventions: 1: FDG PET; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: FACBC PET-CT Imaging; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions: novel PET tracer FACBC; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Failure, Renal Artery Stenosis
Interventions: 62Cu-ethylglyoxal bis(thiosemicarbazone), 15O-water, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Jeffrey L. Lacy; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib, Dexamethasone, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cancer Nos
Interventions: Resting Energy Expenditure, Thermal Comfort Questionnaire; Procedure · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer, Nasopharyngeal Cancer Stage
Interventions: Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection; Radiation · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Invasive Lobular Breast Carcinoma
Interventions: [18F]Fluoroestradiol (FES) PET/CT; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Paclitaxel, Positron Emission Tomography, Questionnaire Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: COVID-19
Interventions: C11 ER176 Tracer; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
Interventions: Radiopharmaceuticals; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Naresh Bumma; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Interventions: Ga-68 PSMA-HBED-CC PET; Drug
Lead sponsor: Michael Graham PhD, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions: Biomarker Data Collection, MK6240; Other · Radiation
Lead sponsor: GAP Innovations, PBC; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 22
States / cities: Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Fluorine F 18 Sodium Fluoride; Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more

Conditions: Blast Injury
Interventions: PBR28 TSPO PET; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: [C11]PK-1195 PET scan; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Drug Dependence
Interventions: [11-C]OMAR; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Ultralow Dose PET Imaging of 18F-FDOPA

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

Ultralow Dose PET Imaging for 18F-NaF Uptake

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

Renal Blood Flow Measurement With Positron Emission Tomography (PET)

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Maladaptive Adipose Tissue Activity in Cancer

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

Tau Imaging With JNJ067

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

Measuring Active Microglia in Progressive Multiple Sclerosis

CB1R in Synthetic Psychoactive Cannabinoids